Bifogade filer
Number of shares and votes in Oncopeptides
Kurs
+5,40%
Likviditet
8,40 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | Årsstämma |
| 2025-05-08 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-27 | 08:00 | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-14 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-23 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-04-15 | - | Extra Bolagsstämma 2024 |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-08 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-09-23 | - | Extra Bolagsstämma 2022 |
| 2022-08-11 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-28 | - | Årsstämma |
| 2022-05-20 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-24 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-12-04 | - | Extra Bolagsstämma 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-12-17 | - | Extra Bolagsstämma 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-22 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2019-05-21 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-10-26 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-13 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
| 2018-05-17 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-18 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
STOCKHOLM – June 28, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 238,107 class C shares in Oncopeptides to a total 238,107 ordinary shares, in order to deliver ordinary shares to participants in Oncopeptides’ incentive program Board SHP 2023.
As of today, the total number of shares in Oncopeptides amounts to 215,186,246 shares, of which 211,263,903 are ordinary shares and 3,922,343 are class C shares. As of today, the number of votes in Oncopeptides amounts to 211,656,137.19, and the share capital amounts to SEK 23,909,583.859895.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68
This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-06-28 08:00 CEST.
About Oncopeptides
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com
Attachments
Number of shares and votes in Oncopeptides